Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

FDA approves Gilead’s hep C drug Epclusa

Written by: | no-reply@reuters.com | Dated: Tuesday, June 28th, 2016

The U.S. Food and Drug Administration approved Gilead Sciences Inc’s drug for treating chronic hepatitis C virus infection.

The drug, Epclusa, is approved for use in combination with ribavirin.

Epclusa is the first drug to treat all six major types of hepatitis C virus infection.

Gilead shares were up 4 pct at $81.03 in morning trading on the Nasdaq.

 

 

(Reporting by Shailesh Kuber in Bengaluru; Editing by Don Sebastian)

Source: Reuters Health

http://www.reuters.com/article/us-gilead-sciences-fda-idUSKCN0ZE1U6

 

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom